PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND

Summary

PRIMETEST II is an interventional study involving low-volume metastatic seminoma. It explores a novel approach using robot-assisted primary retroperitoneal lymph node dissection, aiming to reduce long-term side effects and improve quality of life. By identifying factors predicting cancer recurrence, the study hopes to tailor treatments for better outcomes. The approach could potentially spare patients from chemotherapy induced long-term side effects while maintaining excellent survival rates, presenting a promising shift in testicular cancer care for this specific patient group.

Timeline

Start

2023-08-28

Primary completion

2026-08-31

Completion

2029-08-31

Drugs

Indications